Synthesis and evaluation of symmetric acyclic nucleoside bisphosphonates as inhibitors of the Plasmodium falciparum, Plasmodium vivax and human 6-oxopurine phosphoribosyltransferases and the antimalarial activity of their prodrugs
作者:Petr Špaček、Dianne T. Keough、Marina Chavchich、Martin Dračínský、Zlatko Janeba、Lieve Naesens、Michael D. Edstein、Luke W. Guddat、Dana Hocková
DOI:10.1016/j.bmc.2017.05.048
日期:2017.8
Two new series of symmetric acyclic nucleoside bisphosphonates (ANbPs) have been synthesised as potential inhibitors of the Plasmodium falciparum (Pf) and vivax (Pv) 6-oxopurine phosphoribosyltransferases. The structural variability between these symmetric ANbPs lies in the number of atoms in the two acyclic linkers connecting the N9 atom of the purine base to each of two phosphonate groups and the
已经合成了两个新系列的对称无环核苷双膦酸酯(ANbPs)作为恶性疟原虫(Pf)和间日疟原虫(Pv)6-氧代嘌呤磷酸核糖基转移酶的潜在抑制剂。这些对称ANbP之间的结构变异性在于将嘌呤碱基的N 9原子与两个膦酸酯基团的每一个连接的两个无环接头中的原子数,以及无环部分相对于嘌呤碱基的支化点,发生在alpha或beta位置。在每个系列中,已连接了六个不同的6-氧代嘌呤碱。通常,鸟嘌呤或次黄嘌呤的ANbP的K i较低的值要比那些包含8-溴或7-脱氮6-氧代嘌呤碱的值高。对于这一系列化合物,两种寄生虫酶的最低K i值为0.1μM(Pf)和0.2μM(Pv)。这些抑制剂的两种氨基磷酸酯前药在感染的红细胞细胞培养物中表现出对Pf的抗疟活性,IC 50值为0.8和1.5μM。这两种化合物在CC 50值> 300μM的人A549细胞中显示出低细胞毒性,从而产生了出色的选择性指数。